Abstract
Current ocular GvHD (oGvHD) treatments are suboptimal. We investigated the safety and efficacy of long-term continuous treatment with autologous platelet lysate (PL) drops in patients with oGvHD Dry Eye Syndrome (DES) score 2–3 refractory to topical conventional therapy. Ophthalmic evaluation was performed at 6 month intervals. Symptoms were assessed using the Glaucoma Symptom Scale (GSS). Patients were defined 'responders' when showing a reduction at least one grade on National Institutes of Health Eye Score from baseline at the 6 month visit. Thirty-one patients were included, and 16 (51%) completed 36 months of follow-up (range 6.5–72.7). At 6 months all patients were classified as responders: median GSS symptom score decreased from 70 to 41 (33 at 36 months), median GSS function score reduced from 68 to 46 (33 at 36 months) (all P<0.001). Median Tear Break Up Time improved from 3 to 6 s after 6 months and was maintained over time. All signs improved at 6 and 36 months (clinical and statistical significance). No severe adverse events occurred. Long-term treatment with PL drops is secure and effective for oGvHD and can be an efficient therapy option from initial stages of oGvHD to prevent permanent ocular impairment and improving quality of life.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Wang JC, Teichman JC, Mustafa M, O'Donnell H, Broady R, Yeung SN . Risk factors for the development of ocular graft-versus-host disease (GVHD) dry eye syndrome in patients with chronic GVHD. Br J Ophthalmol 2015; 99: 1514–1518.
Uchino M, Ogawa Y, Uchino Y, Mori T, Okamoto S, Tsubota K . Comparison of stem cell sources in the severity of dry eye after allogeneic haematopoietic stem cell. Br J Ophthalmol 2012; 96: 34–37.
Pezzotta S, Rossi GC, Scudeller L, Antoniazzi E, Bianchi PE, Perotti C et al. A cross-sectional study on vision-related quality of life in patients with ocular GVHD. Bone Marrow Transplant 2015; 50: 1224–1226.
Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2015; 21: 389–401.
Tatematsu Y, Ogawa Y, Abe T, Kamoi M, Uchino M, Saijo-Ban Y et al. Grading criteria for chronic ocular graft-versus-host disease: comparing the NIH eye score, Japanese dry eye score, and DEWS 2007 score. Sci Rep 2014; 4: 6680.
Curtis LM, Datiles MB, Steinberg SM, Mitchell SA, Bishop RJ, Cowen EW et al. Predictive models for ocular chronic graft-versus-host disease diagnosis and disease activity in transplant clinical practice. Haematologica 2015; 100: 1228–1236.
Dias AL, Pophali P, Gustavo W, Hasan H, Nosha F, Nau C et al Ocular complications in hematopoietic stem cell transplant patients-a 10 year experience at Mayo Clinic. 2016. EBMT 42nd Annual Meeting.
Matsumoto Y, Dogru M, Goto E, Ohashi Y, Kojima T, Ishida R et al. Autologous serum application in the treatment of neurotrophic keratopathy. Ophthalmology 2004; 111: 1115–1120.
Anitua E, De la Fuente M, Muruzabal F, Riestra A, Merayo-Lloves J, Orive G . Plasma rich in growth factors (PRGF) eye drops stimulates scarless regeneration compared to autologous serum in the ocular surface stromal fibroblasts. Curr Pharm Biotechnol 2012; 13: 1257–1265.
Jung JW, Lee YJ, Yoon SC, Kim TI, Kim EK, Seo KY . Long-term result of maintenance treatment with tacrolimus ointment in chronic ocular graft-versus-host disease. Am J Ophthalmol 2015; 159: 519–527.
Pezzotta S, Del Fante C, Scudeller L, Cervio M, Antoniazzi ER, Perotti C . Autologous platelet lysate for treatment of refractory ocular GVHD. Bone Marrow Transplant 2012; 47: 1558–1563.
Rossi GC, Pasinetti GM, Scudeller L, Milano G, Mazzone A, Raimondi M et al. The Italian version of the Glaucoma Symptom Scale Questionnaire: translation, validation, and reliability. J Glaucoma 2013; 22: 44–51.
Rossi GC, Pasinetti GM, Scudeller L, Bianchi PE . Symptoms Ocular surface disease and glaucoma: how to evaluate impact on quality of life. J Ocul Pharmacol Ther 2013; 29: 390–394.
Bron AJ, Evans VE, Smith JA . Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 2003; 22: 640–650.
Lin X, Cavanagh HD . Ocular manifestations of graft-versus-host disease: 10 years' experience. Clin Ophthalmol 2015; 9: 1209–1213.
Sandri G, Bonferoni MC, Rossi S, Ferrari F, Mori M, Del Fante C et al. Platelet lysate formulations based on mucoadhesive polymers for the treatment of corneal lesions. J Pharm Pharmacol 2010; 63: 189–198.
Burnouf T, Strunk D, Koh MB, Schallmoser K . Human platelet lysate: Replacing fetal bovine serum as a gold standard for human cell propagation? Biomaterials 2016; 76: 371–387.
Doughty MJ, Glavin S . Efficacy of different dry eye treatments with artificial tears or ocular lubricants: a systematic review. Ophthalmic Physiol Opt 2009; 29: 573–583.
Robinson MR, Lee SS, Rubin BI, Wayne AS, Pavletic SZ, Bishop MR et al. Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease. Bone Marrow Transplant 2004; 33: 1031–1035.
Dastjerdi MH, Hamrah P, Dana R . High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen. Cornea 2009; 28: 1091–1096.
Inamoto Y, Sun YC, Flowers ME, Carpenter PA, Martin PJ, Li P et al. Bandage soft contact lenses for ocular graft-versus-host disease. Biol Blood Marrow Transplant 2015; 21: 2002–2007.
Stoyanova E, Otten HM, Wisse R, Rothova A, Riemens A . Bandage and scleral contact lenses for ocular graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. Acta Ophthalmol 2015; 93: e604.
Magro L, Delcampe A, Robin M, N’guyen S, Huynh A, Rubio M-T et al Sclero-corneal lenses safe and efficient for the treatment of keratoconjunctivitis sicca in patients with refractory ocular GVHD: a study on be half of the SFGM-TC. 2016 EBMT 42nd Annual Meeting.
Ogawa Y, Okamoto S, Mori T, Yamada M, Mashima Y, Watanabe R et al. Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Bone Marrow Transplant 2003; 31: 579–583.
Ryu EH, Kim JM, Laddha PM, Chung ES, Chung TY . Therapeutic effect of 0.03% tacrolimus ointment for ocular graft versus host disease and vernal keratoconjunctivitis. Korean J Ophthalmol 2012; 26: 241–247.
Joseph MA, Kaufman HE, Insler M . Topical tacrolimus ointment for treatment of refractory anterior segment inflammatory disorders. Cornea 2005; 24: 417–420.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Pezzotta, S., Del Fante, C., Scudeller, L. et al. Long-term safety and efficacy of autologous platelet lysate drops for treatment of ocular GvHD. Bone Marrow Transplant 52, 101–106 (2017). https://doi.org/10.1038/bmt.2016.221
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2016.221
This article is cited by
-
Advances in the ocular complications after hematopoietic stem cell transplantation
Annals of Hematology (2024)
-
New advances in medical management of dry eye: optimizing treatment strategies for enhanced relief
International Ophthalmology (2024)
-
The ocular graft-versus-host disease: the path from current knowledge to future managements
Eye (2023)
-
Platelet Lysate as a Promising Medium for Nanocarriers in the Management and Treatment of Ocular Diseases
Current Ophthalmology Reports (2022)
-
Recent developments in regenerative ophthalmology
Science China Life Sciences (2020)